Chelsea Hill
Primary Care · Magnolia, MSNPI 1235646688
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Mylan Specialty L.p. at 27.9% of the total. Reporting peaked in 2021 at $775 and has fallen 73.2% since, to $208 in 2025.
Across 146 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$677
- Johnson & Johnson$234
- Sunovion Pharmaceuticals Inc.$164
- AstraZeneca$153
- Xeris Pharmaceuticals, Inc.$149
- Novartis$105
- plus $947 from 24 others
What the payments were for
- Food & beverage$2,428100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mylan Specialty L.p. | 40 | $677 |
| Johnson & Johnson | 14 | $234 |
| Sunovion Pharmaceuticals Inc. | 10 | $164 |
| AstraZeneca | 10 | $153 |
| Xeris Pharmaceuticals, Inc. | 7 | $149 |
| Novartis | 6 | $105 |
| AbbVie | 7 | $101 |
| Avanir Pharmaceuticals, Inc. | 6 | $85 |
| Novo Nordisk | 5 | $80 |
| Eisai Inc. | 4 | $69 |
| Baxter Healthcare | 4 | $67 |
| Astellas Pharma US Inc | 3 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $52 |
| Verona Pharma, Inc. | 3 | $50 |
| GSK | 3 | $50 |
| Lilly USA, LLC | 3 | $45 |
| Philips North America LLC | 2 | $37 |
| Biodelivery Sciences International, Inc. | 3 | $37 |
| Dexcom, Inc. | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Viatris Specialty LLC | 1 | $18 |
| Indivior Inc. | 1 | $18 |
| Bayer | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Pfizer | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
| Merck | 1 | $13 |
How this compares
$2,428 in reported general payments places this provider in the 80th percentile of 80 primary care providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 100 | $102,842 |
| MounjaroTirzepatide | 51 | $64,624 |
| EliquisApixaban | 84 | $58,157 |
| OzempicSemaglutide | 48 | $55,028 |
| LinzessLinaclotide | 64 | $47,532 |
| TrulicityDulaglutide | 33 | $42,644 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $33,894 |
| FarxigaDapagliflozin Propanediol | 40 | $30,015 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $28,049 |
| XareltoRivaroxaban | 42 | $27,247 |
| VraylarCariprazine Hcl | 17 | $26,632 |
| RybelsusSemaglutide | 14 | $24,101 |
| TradjentaLinagliptin | 30 | $17,853 |
| JanuviaSitagliptin Phosphate | 13 | $16,533 |
| EntrestoSacubitril/Valsartan | 11 | $10,969 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $14 | $120,695130 claims |
| Lilly USA, LLCMounjaro, Trulicity | $45 | $107,26884 claims |
| Novo NordiskOzempic, Rybelsus | $80 | $79,12962 claims |
| AbbVieLinzess, Vraylar, Synthroid | $101 | $74,96699 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $153 | $63,90981 claims |
| PfizerEliquis | $14 | $58,15784 claims |
| GSKTrelegy Ellipta | $50 | $28,04939 claims |
| Johnson & JohnsonXarelto | $234 | $27,24742 claims |
| MerckJanuvia | $13 | $16,53313 claims |
| NovartisEntresto | $105 | $10,96911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 80 primary care providers in Mississippi.
Other primary care in Magnolia
- Alisha McArthur WilkesRidgeland$17K
- Katrina BlackardSouthaven$14K
- Sarah HarringtonTupelo$11K
- Julie HarperNewhebron$10K
- Hannah IvisonJackson$10K
- Irene WilsonSouthaven$4K
- Mary EatonTupelo$4K
- Tanya SandersonTupelo$3K
- Amanda EllisKosciusko$3K
- Charity MilamSouthaven$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.